Degarelix

證據等級: L5

預測適應症: 10 個

Degarelix: From GnRH-Dependent Hormonal Conditions to Hypertrichosis

One-Sentence Summary

Degarelix is a GnRH (gonadotropin-releasing hormone) antagonist that suppresses LH/FSH and downstream gonadal hormone secretion; its established clinical use (e.g., advanced hormone-dependent prostate cancer) is not recorded in this evidence pack. The TxGNN model's top prediction is Hypertrichosis (disease), but this is supported by 0 clinical trials and 0 publications, and the drug's own repurposing rationale flags the mechanistic link as likely model noise rather than a genuine biological connection.

Quick Overview

Item	Content
Original Indication	Not provided in evidence pack (data gap — see DG001/DG002). Degarelix is a GnRH antagonist; its class is used in hormone-dependent gonadal-axis conditions, but no confirmed original indication text was supplied.
Predicted New Indication	Hypertrichosis (disease)
TxGNN Prediction Score	99.99%
Evidence Level	L5
Norway Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the evidence pack (DG002, High severity). Based on the repurposing rationale text supplied alongside the predictions, Degarelix is a GnRH antagonist that inhibits LH/FSH release and downstream gonadal steroid production. This mechanism is well established for gonadal-axis-dependent conditions.

However, hypertrichosis (excessive hair growth) is typically driven by inherited follicular abnormalities rather than gonadal hormone signaling. The evidence pack's own rationale explicitly characterizes this link as "embedding similarity noise" (相似度雜訊) rather than a substantiated mechanistic connection — there is no known pathway by which GnRH antagonism would influence hair follicle biology in this condition.

A biologically more coherent candidate lower in the ranking is central precocious puberty (rank 9, L4 evidence). This is a GnRH-dependent condition for which GnRH agonists (e.g., leuprolide) are already standard therapy; a GnRH antagonist like degarelix could theoretically suppress the axis more directly, without the initial flare-up seen with agonists. This remains a class-level mechanistic hypothesis only — no degarelix-specific clinical or case-report evidence currently exists for this indication.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

(Note: 20 literature records were attached to a lower-ranked candidate — "malformation syndrome with odontal/periodontal component," rank 4 — but all concern general periodontal disease pathophysiology and treatment, with no mention of degarelix or GnRH pathways. These are assessed as database co-occurrence noise rather than drug-specific evidence and are therefore not included here.)

Norway Market Information

Degarelix currently holds no marketing authorizations in Norway (0 licenses on record; market status: Not Marketed).

Safety Considerations

Please refer to the package insert for safety information.

(Key warnings, contraindications, and drug-drug interaction data are all flagged as data gaps in this evidence pack — see DG001, "Blocking" severity, which prevents completion of initial safety screening (S1) until TFDA/local label data is obtained.)

Conclusion and Next Steps

Decision: Hold

Rationale: The top-ranked prediction (hypertrichosis) has no supporting clinical trials or literature and is assessed by the evidence pack itself as a mechanistically implausible, likely noise-driven association (Evidence Level L5). Even the most biologically plausible candidate in this set — central precocious puberty — remains at L4 (mechanism/class-level reasoning only, no direct clinical evidence for degarelix), and safety data required for any progression is currently blocked by a data gap.

To proceed, the following is needed:

Resolve DG001 (Blocking): obtain TFDA/local package insert warnings and contraindications before any S1 safety screening can proceed
Resolve DG002 (High): confirm degarelix's mechanism of action and approved original indication(s) via DrugBank API
If pursuing the central precocious puberty hypothesis, commission a targeted literature/preclinical search specific to degarelix (not GnRH agonists generally) to test mechanistic plausibility before allocating further resources
Given the top candidate's mechanistic implausibility, consider deprioritizing hypertrichosis and re-screening lower-ranked, mechanistically coherent candidates instead
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.